WallStreetZenWallStreetZen

NASDAQ: INCY
Incyte Corp Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for INCY

Based on 15 analysts offering 12 month price targets for Incyte Corp

Min Forecast
$89.00-1.96%
Avg Forecast
$108.67+19.7%
Max Forecast
$135.00+48.71%

Should I buy or sell INCY stock?

Based on 15 analysts offering ratings for Incyte Corp.

Buy
Strong Buy
6 analysts 40%
Buy
2 analysts 13.33%
Hold
7 analysts 46.67%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Our proven Zen Rating quant model agrees with analyst consensus with a "Buy" rating. Learn More

Be the first to know when Wall Street analysts revise their INCY stock forecasts and price targets.

INCY stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-03-16
lockedlocked$00.00+00.00%2026-03-09
lockedlocked$00.00+00.00%2026-03-05
lockedlocked$00.00+00.00%2026-02-18
lockedlocked$00.00+00.00%2026-02-11
Stifel Nicolaus
Top 25%
76
Strong BuyMaintains$120.00+32.19%2026-02-11
Wells Fargo
Top 3%
98
HoldMaintains$101.00+11.26%2026-02-11
Piper Sandler
Top 11%
90
Strong BuyMaintains$110.00+21.17%2026-02-06
TD Cowen
Bottom 7%
7
Strong BuyMaintains$128.00+41.00%2026-01-13
Morgan Stanley
Bottom 6%
6
HoldMaintains$94.00+3.55%2026-01-06

1 of 2

Forecast return on equity

Is INCY forecast to generate an efficient return?

Company
15.1%
Industry
67.77%
Market
181.01%
INCY's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is INCY forecast to generate an efficient return on assets?

Company
11.21%
Industry
31.67%
INCY is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

INCY earnings per share forecast

What is INCY's earnings per share in the next 3 years based on estimates from 30 analysts?

Avg 1 year Forecast
$7.66+16.22%
Avg 2 year Forecast
$8.98+36.22%
Avg 3 year Forecast
$9.60+45.7%
INCY's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

INCY revenue forecast

What is INCY's revenue in the next 3 years based on estimates from 29 analysts?

Avg 1 year Forecast
$5.7B+10.97%
Avg 2 year Forecast
$6.3B+22.6%
Avg 3 year Forecast
$6.5B+26.08%
INCY's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

INCY earnings growth forecast

How is INCY forecast to perform vs Biotechnology companies and vs the US market?

Company
13.91%
Industry
11.93%
Market
36.08%
INCY's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
INCY's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
INCY's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

INCY revenue growth forecast

How is INCY forecast to perform vs Biotechnology companies and vs the US market?

Company
8.49%
Industry
35.63%
Market
13.33%
INCY's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
INCY's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

INCY vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
INCY$90.78$108.67+19.70%Buy
RVMD$95.78$125.07+30.58%Strong Buy
ROIV$27.70$32.80+18.41%Strong Buy
GMAB$25.10$40.93+63.06%Strong Buy
MRNA$51.38$32.00-37.72%Hold
View Top Biotech Stocks

Incyte Stock Forecast FAQ

Is Incyte Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 15 Wall Street analysts covering (NASDAQ: INCY) stock is to Buy INCY stock.

Out of 15 analysts, 6 (40%) are recommending INCY as a Strong Buy, 2 (13.33%) are recommending INCY as a Buy, 7 (46.67%) are recommending INCY as a Hold, 0 (0%) are recommending INCY as a Sell, and 0 (0%) are recommending INCY as a Strong Sell.

If you're new to stock investing, here's how to buy Incyte stock.

What is INCY's earnings growth forecast for 2026-2028?

(NASDAQ: INCY) Incyte's forecast annual earnings growth rate of 13.91% is forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.93%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 36.08%.

Incyte's earnings in 2026 is $1,286,650,000.On average, 30 Wall Street analysts forecast INCY's earnings for 2026 to be $1,524,251,948, with the lowest INCY earnings forecast at $784,037,469, and the highest INCY earnings forecast at $1,907,852,370. On average, 27 Wall Street analysts forecast INCY's earnings for 2027 to be $1,786,533,139, with the lowest INCY earnings forecast at $840,597,386, and the highest INCY earnings forecast at $2,303,015,533.

In 2028, INCY is forecast to generate $1,910,817,686 in earnings, with the lowest earnings forecast at $557,797,801 and the highest earnings forecast at $2,731,593,229.

What is INCY's revenue growth forecast for 2026-2028?

(NASDAQ: INCY) Incyte's forecast annual revenue growth rate of 8.49% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.63%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.33%.

Incyte's revenue in 2026 is $5,141,242,000.On average, 29 Wall Street analysts forecast INCY's revenue for 2026 to be $1,135,377,642,630, with the lowest INCY revenue forecast at $1,061,941,297,296, and the highest INCY revenue forecast at $1,233,690,798,714. On average, 27 Wall Street analysts forecast INCY's revenue for 2027 to be $1,254,388,305,258, with the lowest INCY revenue forecast at $1,121,048,599,638, and the highest INCY revenue forecast at $1,557,089,338,464.

In 2028, INCY is forecast to generate $1,290,011,898,252 in revenue, with the lowest revenue forecast at $994,077,357,570 and the highest revenue forecast at $1,787,548,113,252.

What is INCY's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: INCY) forecast ROA is 11.21%, which is lower than the forecast US Biotechnology industry average of 31.67%.

What is INCY's Price Target?

According to 15 Wall Street analysts that have issued a 1 year INCY price target, the average INCY price target is $108.67, with the highest INCY stock price forecast at $135.00 and the lowest INCY stock price forecast at $89.00.

On average, Wall Street analysts predict that Incyte's share price could reach $108.67 by Mar 16, 2027. The average Incyte stock price prediction forecasts a potential upside of 19.7% from the current INCY share price of $90.78.

What is INCY's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: INCY) Incyte's current Earnings Per Share (EPS) is $6.59. On average, analysts forecast that INCY's EPS will be $7.66 for 2026, with the lowest EPS forecast at $3.94, and the highest EPS forecast at $9.59. On average, analysts forecast that INCY's EPS will be $8.98 for 2027, with the lowest EPS forecast at $4.22, and the highest EPS forecast at $11.57. In 2028, INCY's EPS is forecast to hit $9.60 (min: $2.80, max: $13.73).

What is INCY's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: INCY) forecast ROE is 15.1%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.